US Foods (USFD) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
15 May, 2026Opening remarks and agenda
Meeting conducted virtually to increase accessibility for stockholders.
Board members and executive team introduced, highlighting their diverse expertise.
Representatives from Deloitte & Touche and Broadridge Financial Solutions present for Q&A and election oversight.
Financial performance review
Adjusted EBITDA grew 11% to over $1.9 billion, with margin expansion of 30 basis points in 2025.
Adjusted EPS reached a record $3.98, up 26%, leading the industry.
Achieved strong results despite macroeconomic softness, severe weather, geopolitical conflict, and rising fuel costs.
Repurchased $930 million in shares and completed two tuck-in acquisitions totaling over $130 million.
Board and executive committee updates
Board consists of experienced leaders overseeing strategy execution.
CEO, CFO, and Chief Legal Counsel present; proxies appointed for voting.
Latest events from US Foods
- Adjusted EBITDA rose 9.9% as FY26 growth guidance narrowed amid softer demand.USFD
Q3 2026 - Record FY2023 Adjusted EBITDA rose 19% as net leverage fell to 2.8x.USFD
Q4 2023 - Strong growth in independents, digital, and AI, with Pronto and margin expansion as key drivers.USFD
Barclays 19th Annual Global Consumer Conference - Record Adjusted EBITDA and margin expansion driven by strong sales and disciplined capital allocation.USFD
Q2 2026 - Stable demand, tech-driven growth, and strategic focus fuel strong financial and operational momentum.USFD
23rd annual dbAccess Global Consumer Conference - Adjusted EBITDA up 6.2% and net sales up 2.8%, with $125M in share repurchases.USFD
Q1 2026 - Q3 delivered 4.8% sales growth, double-digit EBITDA and EPS gains, and raised 2025 guidance.USFD
Q3 2025 - 2025–2027 targets: ~5% sales CAGR, 10%+ EBITDA CAGR, $1B buyback, digital and operational focus.USFD
Investor Day 2024 - Net sales, profit, and margins surged, with a $1B buyback and guidance reaffirmed.USFD
Q1 2025